首页> 外文期刊>Pakistan journal of medical sciences. >Enhancing effect of β-elemene emulsion on chemotherapywith harringtonine, aclacinomycin and Ara-c in treatment of refractory/relapsed acute myeloid leukemia
【24h】

Enhancing effect of β-elemene emulsion on chemotherapywith harringtonine, aclacinomycin and Ara-c in treatment of refractory/relapsed acute myeloid leukemia

机译:β-榄香烯乳剂对harringtonine,aclacinomycin和Ara-c联合化疗治疗难治性/复发性急性髓细胞白血病的疗效

获取原文
       

摘要

Objective: This study is to determine the curative effect of β-elemene emulsion on chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML).Methods: In the β-elemene emulsion plus HAA chemotherapy (harringtonine, aclacinomycin, Ara-c group) group, 120 cases received β-elemene emulsion (400 mg) plus the HAA treatment. A 14-day treatment was a course of treatment, followed by an 8-14 day pause, and then the next course of treatment. The HAA treatment included Ara-C, 100 mg/m2, once every 12 h from day 1 to day 7; aclacinomycin, 20 mg/m2, from day 1 to day 7; and homoharringtonine, 4 mg/m2, from day 1 to day 7. The patients in the control HAA group received HAA treatment only. For both groups, effective antibiotics were given to patients when it was necessary.Results: The total effective rate in the β-elemene emulsion plus HAA group was 80.8%. But the total effective rate in the HAA only group was 52.9%. These results suggest that the β-elemene emulsion plus HAA treatment has a much better curative effect in comparison with the HAA only treatment (P < 0.05). Furthermore, β-elemene emulsion has slightly adverse response, without causing blood and bone marrow depression.Conclusion: β-elemene emulsion has a curative effect in treatment of refractory/relapsed AML in combination with harringtonine, aclacinomycin, and Ara-c.doi: http://dx.doi.org/10.12669/pjms.306.5207How to cite this:Zheng C, Cai X, Wu S, Liu Z, Shi Y, Zhou W. Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin and Ara-c in treatment of refractory/relapsed acute myeloid leukemia. Pak J Med Sci 2014;30(6):1270-1272. doi: http://dx.doi.org/10.12669/pjms.306.5207This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译:目的:本研究旨在确定β-榄香烯乳剂对化疗治疗难治性/复发性急性髓细胞白血病(AML)的疗效。方法:在β-榄香烯乳剂加HAA化疗(harringtonine,aclacinomycin,Ara-c)中应用组)组,120例患者接受β-榄香烯乳剂(400 mg)加HAA治疗。 14天的治疗是一个疗程,然后停顿8-14天,然后再进行下一个疗程。从第1天到第7天,每12小时一次,HAA治疗包括100 mg / m2的Ara-C;从第1天到第7天,阿克拉霉素20 mg / m2;从第1天到第7天服用高纯harringtonine和4 mg / m2。对照组HAA组的患者仅接受HAA治疗。结果:β-榄香烯乳剂加HAA组总有效率80.8%。但是,仅HAA组的总有效率为52.9%。这些结果表明,与仅使用HAA的治疗相比,β-榄香烯乳液加HAA的治疗具有更好的疗效(P <0.05)。此外,β-榄香烯乳剂有轻微的不良反应,不会引起血液和骨髓抑制。结论:β-榄香烯乳剂与harringtonine,aclacinomycin和Ara-c.doi联合使用可治疗难治性/复发性AML: http://dx.doi.org/10.12669/pjms.306.5207引用方式:郑C,蔡X,吴S,刘Z,石Y,周W。增强β-榄香烯乳状液对harringtonine的化疗作用,阿克拉霉素和Ara-c治疗难治性/复发性急性髓细胞白血病。 Pak J Med Sci 2014; 30(6):1270-1272。 doi:http://dx.doi.org/10.12669/pjms.306.5207这是根据知识共享署名许可(http://creativecommons.org/licenses/by/3.0)条款发布的开放获取文章,只要适当引用了原始作品,便可以在任何介质中不受限制地使用,分发和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号